Research Topics
| Garry G GrahamSummaryAffiliation: St Vincent's Hospital Country: Australia Publications
| Collaborators
|
Detail Information
Publications
[Tolerability of paracetamol]Garry G Graham
Departement de Pharmacologie Clinique, Hôpital Saint Vincent et Ecole des Sciences médicales, Université de Nouvelle Galles du Sud, Sydney, Australie
Drugs 63:43-6. 2003..Despite the conversion of paracetamol to reactive compounds, hypersensitivity reactions are rare, although urticaria is produced in occasional patients...
Acetaminophen (paracetamol) inhibits myeloperoxidase-catalyzed oxidant production and biological damage at therapeutically achievable concentrationsMaud Koelsch
Heart Research Institute, Newtown, Sydney, NSW, Australia
Biochem Pharmacol 79:1156-64. 2010..Overall, these data indicate that acetaminophen may be an important modulator of MPO activity in vivo...- Mechanism of action of paracetamolGarry G Graham
Department of Physiology and Pharmacology, University of New South Wales, St Vincent s Hospital, Darlinghurst, NSW 2010, Australia
Am J Ther 12:46-55. 2005..The action of paracetamol at a molecular level is unclear but could be related to the production of reactive metabolites by the peroxidase function of COX-2, which could deplete glutathione, a cofactor of enzymes such as PGE synthase... - Tolerability of paracetamolGarry G Graham
Department of Clinical Pharmacology, St Vincent s Hospital, School of Medical Sciences, Sydney, Australia
Drug Saf 28:227-40. 2005..Paracetamol appears to be well tolerated during pregnancy although prospective studies are required... - Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with goutSophie L Stocker
Department of Clinical Pharmacology, St Vincent s Hospital, NSW 2010, Sydney, Australia
J Rheumatol 38:904-10. 2011..To investigate the pharmacokinetic and pharmacodynamic interaction between probenecid and oxypurinol (the active metabolite of allopurinol) in patients with gout... - Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteersDaniel Y Ng
Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital, Xavier Level 2, Darlinghurst, NSW 2010, Australia
Eur J Clin Pharmacol 67:709-13. 2011..To determine whether low-dose aspirin and hydrochlorothiazide (HCTZ) affect the renal clearance of oxypurinol and/or urate... - Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjectsSophie L Stocker
Faculty of Pharmacy, University of Sydney, Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital, Sydney, New South Wales, Australia
Clin Pharmacokinet 47:111-8. 2008..The objective of this study was to investigate the pharmacokinetics and hypouricaemic effect of oxypurinol (the active metabolite of allopurinol) and probenecid when administered alone and in combination in healthy subjects... 
The pharmacokinetics of oxypurinol in people with goutSophie L Stocker
Faculty of Pharmacy, University of Sydney, NSW, Australia
Br J Clin Pharmacol 74:477-89. 2012..Our aim was to identify and quantify the sources of variability in oxypurinol pharmacokinetics and explore relationships with plasma urate concentrations...- Optimizing therapy with allopurinol: factors limiting hypouricemic efficacyYewon Chung
Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital, Sydney, Australia
Am J Med Sci 335:219-26. 2008..Probenecid increases the hypouricemic effect of allopurinol but the favorable interaction may be significant only in patients with glomerular filtration rates greater than about 50 mL/min... - A proposal for identifying the low renal uric acid clearance phenotypePraveen L Indraratna
Faculty of Medicine, University of New South Wales, NSW, 2052, Australia
Arthritis Res Ther 12:149. 2010..We also propose that a single daytime spot urine sample for calculation of fractional renal clearance of urate should be preferred to calculation from 24-hour urine collections... - Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol)Garry G Graham
Department of Physiology and Pharmacology, School of Medical Sciences, Faculty of Medicine, Sydney, 2052, Australia
Curr Pharm Des 8:1063-75. 2002..No such associations have been made with acetaminophen, possibly because it is a weak inhibitor of COX-1 in platelets... - FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?Garry G Graham
Department of Clinical Pharmacology, St Vincent s Hospital, Darlinghurst, NSW, 2010, Australia
Inflammopharmacology 18:47-55. 2010..Adoption of these two recommendations may lead to the increased use of NSAIDs with the potential of increasing incidence of NSAIDs-related adverse reactions... - Antifungal use and therapeutic monitoring of plasma concentrations of itraconazole in heart and lung transplantation patientsJonathan Brett
Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital Department of Pharmacology, University of New South Wales Department of Microbiology and Clinical Infectious Diseases, St Vincent s Hospital St Vincent s Clinical School, University of New South Wales, Sydney, New South Wales
Ther Drug Monit 35:133-6. 2013..To further reduce this incidence, it has been suggested that plasma concentrations of itraconazole be monitored and maintained above a putative minimum target concentration of 500 ng/mL... - A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?Ming Han H Lee
Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital, University of New South Wales, Sydney, New South Wales, Australia
Drug Saf 31:643-65. 2008..We conclude that the withdrawal of benzbromarone was not in the best interest of patients with gout... - Emerging roles for phospholipase A2 enzymes in cancerKieran F Scott
St Vincent s Hospital Clinical School, The University of New South Wales, L5 DeLacey Bldg, St Vincent s Hospital, Darlinghurst NSW 2010, Australia
Biochimie 92:601-10. 2010.... - Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinolRichard O Day
School of Medical Sciences, Faculty of Medicine, University of New South Wales and Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital, Sydney, New South Wales, Australia
Clin Pharmacokinet 46:623-44. 2007..The net effect is an increased degree of hypouricaemia, but the interaction is probably limited to patients with normal renal function or only moderate impairment... - Clinical pharmacokinetics of metforminGarry G Graham
Department of Pharmacology and Toxicology, St Vincents Clinical School, University of New South Wales, Sydney, New South Wales, Australia
Clin Pharmacokinet 50:81-98. 2011..We suggest that the mean plasma concentrations of metformin over a dosage interval be maintained below 2.5 mg/L in order to minimize the development of this adverse effect... - Secreted phospholipase A2 enzymes as therapeutic targetsKieran F Scott
St Vincent s Hospital Clinical School, School of Medical Sciences, The University of New South Wales, Sydney, Australia
Expert Opin Ther Targets 7:427-40. 2003.... - Paracetamol should be first-line therapy in osteoarthritisRichard O Day
Med J Aust 182:198-9; author reply 199. 2005